SILK Silk Road Medical

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference

SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference.

Management is scheduled to present on Tuesday, May 14, 2024, at 3:40 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: .

About Silk Road Medical

Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit and connect on X, LinkedIn and Facebook.

Investor Contact:

Marissa Bych

Gilmartin Group



EN
23/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silk Road Medical

 PRESS RELEASE

Silk Road Medical Reports Second Quarter 2024 Financial Results

Silk Road Medical Reports Second Quarter 2024 Financial Results SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2024. “Our solid second quarter performance demonstrates continued TCAR adoption and growth driven by the unwavering dedication of our team,” said Chas McKhann, CEO of Silk Road Medical. “We look forward to continuing our mission as part of Boston Scientific and, together, expanding pat...

 PRESS RELEASE

Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery ...

Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques SUNNYVALE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company focused on reducing the risk and impact of stroke, today announced the milestone that more than 100,000 TCAR procedures have been performed to date. Since its incep...

 PRESS RELEASE

Silk Road Medical Announces Definitive Agreement to be Acquired by Bos...

Silk Road Medical Announces Definitive Agreement to be Acquired by Boston Scientific Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (“Boston Scientific”) (NYSE: BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity value of ap...

 PRESS RELEASE

Silk Road Medical Reports First Quarter 2024 Financial Results

Silk Road Medical Reports First Quarter 2024 Financial Results SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. “Our team delivered a strong start to 2024 as we deepened relationships with the physicians we serve and continued broadening our patient impact,” said Chas McKhann, CEO of Silk Road Medical. “In the first quarter, we made meaningful commercial progress while also taking steps ...

 PRESS RELEASE

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Co...

Silk Road Medical to Present at the BofA Securities 2024 Healthcare Conference SUNNYVALE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2024 Healthcare Conference. Management is scheduled to present on Tuesday, May 14, 2024, at 3:40 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: . About Silk Roa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch